Long-acting growth hormone and medicine composition

A technology of growth hormone and conjugates, which is applied in the direction of drug combination, growth hormone, hormone peptide, etc., and can solve problems such as poor practicability, increased dosage, product inhomogeneity, process and quality control, etc.

Inactive Publication Date: 2004-02-25
CHANGCHUN GENESCIENCE PHARM CO LTD +3
View PDF0 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although this method proves the feasibility of modifying growth hormone with polyethylene glycol, it may need to increase the dose to compensate due to the reduction of activity, and the heterogeneity of the product makes it difficult to guarantee the process and quality control in large-scale production, so , the practicality of this study is not strong

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Long-acting growth hormone and medicine composition
  • Long-acting growth hormone and medicine composition
  • Long-acting growth hormone and medicine composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] The preparation of embodiment 1 high molecular weight bifurcated polyethylene glycol

[0064] In order to prolong the half-life of growth hormone, high molecular weight branched polyethylene glycol is more suitable. A method for synthesizing polyethylene glycol with a multi-branched molecular weight of 80,000 is described below, and this method can also be used to synthesize other polyethylene glycols with different molecular weights or shapes.

[0065] 11.8 mg of Fmoc-Lys(Fmoc)-OH (MW590, 20 μmol, AdvancedChemTech) was dissolved in 120 μl of dimethylformamide (DMF) containing 24 μmol of NHS (Sigma), and 3.8 μl of diisopropylcarbodiimide ( DIC, MW126, d=0.8, 24 μmol, Advanced ChemTech), the reaction was shaken at room temperature for two hours. Dissolve 68 mg of NH2-PEG-COOH (MW3400, 20 μmol, Shearwater) in 100 μl of dichloromethane (DCM), add 6.9 μl of diisopropylethylamine (DIPEA, MW129, d=0.74, 40 μmol, Sigma), and mix with the previous The partial reaction was mixed...

Embodiment 2

[0069] Embodiment 2 Somatotropin is coupled with 80kDa and 40kDa polyethylene glycol

[0070] Dissolve 234mg of growth hormone lyophilized powder in 4ml of 0.1M sodium phosphate, pH7.0. A HiTrap Sephadex G25 desalting column (2.5×15 cm, Pharmacia Biotech) was equilibrated with human 0.1 M sodium phosphate (pH 7.0), and the growth hormone sample was loaded, observed at 280 nm, and the first peak (18 ml) was collected. Measure the 280nm optical density and use the extinction coefficient of 0.68 to calculate the growth hormone concentration, the result is 280nm optical density 1.2, protein concentration 1.76mg / ml, total protein 32mg.

[0071] When coupling with 80kDa polyethylene glycol, weigh 60mg of activated 80kDamPEG 4 - NHS (0.7 μmol) was added to 1.1 ml of sodium phosphate (pH 7.0) solution containing 6 mg growth hormone (0.3 μmol), and the reaction was shaken at 4° C. overnight.

[0072] When coupling with 40kDa polyethylene glycol, weigh 60mg of activated 40kDamPEG 2 -...

Embodiment 380

[0073] Example 380kDa and 40kDa polyethylene glycol growth hormone conjugates are purified with Superdex75

[0074] The 80kDa and 40kDa polyethylene glycol somatotropin conjugates were purified by Superdex 75 chromatography column (1.5×40cm, Pharmacia Biotech). Equilibrate the chromatographic column with a solution of 150mM sodium chloride, 10mM sodium citrate, 0.2% Tween 20, and pH 6.0, and then load the sample. The sample volume is less than 5% of the column volume. Use 280nm to observe the protein peak and collect first eluting peak. A total of 35ml of 40kDa polyethylene glycol human growth hormone conjugate with a concentration of 0.16mg / ml was collected, with a total protein content of 5.6mg. A total of 28ml of 80kDa polyethylene glycol human growth hormone conjugate with a concentration of 0.08mg / ml was collected, with a total protein content of 2.6mg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a method for adopting macromolecular weight polyglycol to modify growth hormone so as to obtain the modified product capable of obviously prolonging half-life period of the growth hormone.

Description

technical field [0001] The invention belongs to the technical field of biological preparations. It specifically relates to long-acting growth hormone, its preparation method, function and application. Background technique [0002] Human growth hormone is a protein hormone secreted by the human pituitary gland, and it is an indispensable regulatory hormone for the normal growth and development of the human body. The earliest source of growth hormone is extracted from the human pituitary gland, but due to limited sources and difficulties in quality assurance, this product is difficult to be widely used. The emergence of genetic engineering technology has made the large-scale production of human growth hormone possible, and recombinant human growth hormone has become the second product in the bioengineering pharmaceutical industry and has been widely used. It is currently mainly used for dwarfism, extensive trauma recovery, adult Growth hormone deficiency, AIDS patients' thin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/27A61P5/00A61P17/02A61P43/00C07K14/61C07K17/02C08G65/00
Inventor 李伟华董建王绍白
Owner CHANGCHUN GENESCIENCE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap